'GIANT STEP FORWARD': Reclassification of medical cannabis lauded

• Medical cannabis reclassified from Schedule 1 to Schedule 3, correcting decades of incorrect classification and allowing for actual research into cannabis products.
• The reclassification will provide physicians with more information on indications and contraindications, benefiting patients and American healthcare.
• It will normalize tax treatment for cannabis businesses, reducing the current 70% tax rate and allowing legitimate companies to better compete with the black market and make necessary investments.
• The CEO differentiates between edibles (longer duration, consistent dose, good for sleep) and vapes (shorter onset, controllable titration, good for immediate relief like spasticity).

The Trulieve CEO discusses the reclassification of medical cannabis from Schedule 1 to Schedule 3 by the Trump administration. This move is lauded as a 'giant step forward' for the cannabis industry, enabling crucial research, improving product information for consumers and doctors, and normalizing tax treatment for legitimate businesses, which currently face a 70% tax rate.